454 related articles for article (PubMed ID: 25445393)
1. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
[TBL] [Abstract][Full Text] [Related]
2. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
[TBL] [Abstract][Full Text] [Related]
3. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P
Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710
[TBL] [Abstract][Full Text] [Related]
4. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA signatures in hereditary breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
[TBL] [Abstract][Full Text] [Related]
7. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
8. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
9. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
10. Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations.
Erturk E; Cecener G; Egeli U; Tunca B; Tezcan G; Gokgoz S; Tolunay S; Tasdelen I
Mol Cell Biochem; 2014 Oct; 395(1-2):77-88. PubMed ID: 24942235
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA in breast cancer: The association with BRCA1/2.
Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE
Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator.
Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q
Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250
[TBL] [Abstract][Full Text] [Related]
13. [BRCA1/2 gene mutation and clinicopathologic features of triple negative breast cancer].
Ma ZP; Wang W; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):397-400. PubMed ID: 27256048
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
Abdel-Sater F; Najar M; Fayyad-Kazan H
J Cell Physiol; 2020 Jun; 235(6):5204-5212. PubMed ID: 31736084
[TBL] [Abstract][Full Text] [Related]
15. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
16. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
[TBL] [Abstract][Full Text] [Related]
17. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
18. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs-mediated cell fate in triple negative breast cancers.
Sui X; Wang X; Han W; Li D; Xu Y; Lou F; Zhou J; Gu X; Zhu J; Zhang C; Pan H
Cancer Lett; 2015 May; 361(1):8-12. PubMed ID: 25748387
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
